Short on particulars like heart rate, cholesterol level or family history, it described Mr. Trump in laudatory terms, saying that he would be "the healthiest individual ever elected to the presidency".
And as the New York Times noted, even the letter he issued "contained no details about his heart rate, respiratory rate, cholesterol level, past medications or family medical history". Those are all things that are usually included.
As the New York Times noted, it "contained no details about his heart rate, respiratory rate, cholesterol level, past medications or family medical history". And now, given Bornstein's comments suggesting his own letter was written under some duress — or at least, less than ideal circumstances — you can expect rising demands for a do-over, and perhaps more information about Trump's health.
This is surprising because almost every other medication used to prevent cardiovascular disease has a simple test that doctors can use to measure the response (e.g. blood pressure, heart rate, cholesterol).
We consider a WBAN scenario in a remote patient monitoring system as it is shown in Fig. 2, where sensors are attached on the patient's clothing or placed on the patient's body and measure various vital signs (e.g., blood pressure, heart rate, respiration rate, cholesterol level) or external parameters (e.g., patient's location, motion patters).
All patients underwent routine blood and biochemistry tests (leucocytes and red cells count, transaminases, Y-glutamil transpeptidase, alkaline phosphatase, bilirubin, electrolytes, creatinine, erythrosedimentation rate, cholesterol and tryglicerides).
Nor do we see the millions of larger-bodied men and women who value wellness and embrace nutritious foods and movement; who have healthy blood pressure, heart rates, cholesterol, hormones, and other markers of health, but whose BMIs suggests they're "overweight".
Cases had higher heart rate, total cholesterol, LDL cholesterol, HDL cholesterol, fasting glucose, and HbA1c and had thicker bulb IMT (P < 0.03).
There were no between-group differences regarding changes in systolic and diastolic blood pressures, estimated glomerular filtration rate, total cholesterol, HDL cholesterol, or LDL cholesterol from baseline to study end.
Significantly greater improvements in body weight, waist circumference, SBP, DBP, HDL-cholesterol, triglycerides, and hsCRP were observed in exenatide- compared with glimepiride-treated patients, but changes in heart rate, total cholesterol, and LDL-cholesterol were similar between treatment groups.
After three months, the researchers found no statistically significant differences among the three groups in most factors that influence the risk of heart disease -- body mass index, blood pressure, heart rate, total cholesterol, triglycerides, H.D.L. (the good cholesterol), insulin levels and glucose levels.
